



Fueling Open Innovation for Malaria Transmission-Blocking Drugs: Hundreds of Molecules Targeting Early Parasite Mosquito Stages

Michael Delves^{1,2*}, M. Jose Lafuente-Monasterio³, Leanna Upton², Andrea Ruecker^{2,4,5}, Didier Leroy⁶, Francisco-Javier Gamo³ and Robert Sinden²

¹ Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom, ² Department of Life Sciences, Imperial College London, London, United Kingdom, ³ Diseases of the Developing World (DDW), GlaxoSmithKline, Tres Cantos, Spain, ⁴ Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, ⁵ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ⁶ Medicines for Malaria Venture, Geneva, Switzerland

OPEN ACCESS

Edited by:

Isabelle Morlais,
Institut de Recherche pour le
Développement (IRD), France

Reviewed by:

Mathieu Gissot,
Centre National de la Recherche
Scientifique (CNRS), France
Juan Diego Maya,
University of Chile, Chile

*Correspondence:

Michael Delves
michael.delves@lshtm.ac.uk

Specialty section:

This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology

Received: 20 June 2019

Accepted: 30 August 2019

Published: 13 September 2019

Citation:

Delves M,
Lafuente-Monasterio MJ, Upton L,
Ruecker A, Leroy D, Gamo F-J and
Sinden R (2019) Fueling Open
Innovation for Malaria
Transmission-Blocking Drugs:
Hundreds of Molecules Targeting
Early Parasite Mosquito Stages.
Front. Microbiol. 10:2134.
doi: 10.3389/fmicb.2019.02134

Background: Despite recent successes at controlling malaria, progress has stalled with an estimated 219 million cases and 435,000 deaths in 2017 alone. Combined with emerging resistance to front line antimalarial therapies in Southeast Asia, there is an urgent need for new treatment options and novel approaches to halt the spread of malaria. *Plasmodium*, the parasite responsible for malaria propagates through mosquito transmission. This imposes an acute bottleneck on the parasite population and transmission-blocking interventions exploiting this vulnerability are recognized as vital for malaria elimination.

Methods: 13,533 small molecules with known activity against *Plasmodium falciparum* asexual parasites were screened for additional transmission-blocking activity in an *ex vivo Plasmodium berghei* ookinete development assay. Active molecules were then counterscreened in dose response against HepG2 cells to determine their activity/cytotoxicity window and selected non-toxic representative molecules were fully profiled in a range of transmission and mosquito infection assays. Furthermore, the entire dataset was compared to other published screens of the same molecules against *P. falciparum* gametocytes and female gametogenesis.

Results: 437 molecules inhibited *P. berghei* ookinete formation with an IC₅₀ < 10 μM. of which 273 showed > 10-fold parasite selectivity compared to activity against HepG2 cells. Active molecules grouped into 49 chemical clusters of three or more molecules, with 25 doublets and 94 singletons. Six molecules representing six major chemical scaffolds confirmed their transmission-blocking activity against *P. falciparum* male and female gametocytes and inhibited *P. berghei* oocyst formation in the standard membrane feeding assay at 1 μM. When screening data in the *P. berghei* development ookinete assay was compared to published screens of the same library in assays against *P. falciparum* gametocytes and female gametogenesis, it was established that

each assay identified distinct, but partially overlapping subsets of transmission-blocking molecules. However, selected molecules unique to each assay show transmission-blocking activity in mosquito transmission assays.

Conclusion: The *P. berghei* ookinete development assay is an excellent high throughput assay for efficiently identifying antimalarial molecules targeting early mosquito stage parasite development. Currently no high throughput transmission-blocking assay is capable of identifying all transmission-blocking molecules.

Keywords: malaria, transmission, ookinete, drug, screening

INTRODUCTION

Malaria is still a disease of devastating medical and economic impact affecting nearly half of the world's population. *Plasmodium*, the apicomplexan parasite responsible for malaria has a complex life cycle requiring both vertebrate hosts and mosquitoes. With every round of asexual replication within the blood, a proportion of cells are triggered to undergo an alternative developmental pathway and transform into mosquito-transmissible male and female gametocytes. When a mosquito bites, these gametocytes are taken up in the bloodmeal and within minutes transform into male and female gametes in the mosquito midgut. Fertilization ensues and the resultant zygote develops into a motile ookinete around 22 h after feeding. The ookinete migrates to and through the midgut wall forming an oocyst and infecting the mosquito. Parasites then further develop into sporozoites that migrate to the salivary glands ready to infect a new human host.

With the exception of tafenoquine and 8-aminoquinolines, all antimalarial drugs have been developed primarily to target the pathogenic asexual stage of the parasite life cycle. Consequently, they have variable activity against other parasite stages possessing divergent cell biology (Delves M. et al., 2012; Plouffe et al., 2016). In order to achieve local elimination and global eradication of malaria, reducing parasite transmission is essential (Rabinovich et al., 2017). At the point of seeking treatment, malarial patients frequently already possess mosquito-infectious male and female gametocyte stage parasites, therefore a patient can be treated and “cured” of their infection but still be able to pass parasites on to mosquitoes and perpetuate the disease (Eziefula et al., 2013). In addition, a significant proportion of the population in malaria-endemic areas have asymptomatic infections and harbor submicroscopic levels of gametocytes which contribute to the persistence of malaria. As gametocytes develop and reside within the human host, gametocyte-targeted transmission-blocking drugs can be administered directly to the patient (Burrows et al., 2017). However, the reduced and divergent metabolism of the gametocyte leaves them insensitive to most antimalarial treatments (Delves M. et al., 2012; Plouffe et al., 2016). Given that the mosquito bloodmeal is composed primarily of blood, transmission-blocking drugs administered to the patient can also access and target early mosquito stage parasite development when the parasite “reawakens” its metabolism and displays more targetable cell biology. However, such a strategy requires drugs with long half-lives so that efficacious concentrations

can be maintained within every mosquito bite where infectious gametocytes are present. Alternatively, recent data has shown surfaces treated with the transmission-blocking antimalarial atovaquone are effective at delivering an efficacious dose directly to the mosquito through contact exposure (Paton et al., 2019).


In 2010, GlaxoSmithKline (GSK) reported and released the chemical structures of 13,533 molecules from within their compound library with activity against *P. falciparum* asexual development (Gamo et al., 2010). Since then, the Tres Cantos Antimalarial Set (TCAMS) has been extensively screened in a range of high throughput assays against different parasite stages (Almela et al., 2015; Raphemot et al., 2015; Miguel-Blanco et al., 2017) and yielded new antimalarial candidate molecules (Sanz et al., 2011; Calderón et al., 2012; Williamson et al., 2016). To date, little is known about their activity on early parasite development in the mosquito. Using the rodent malaria model *P. berghei* and an established *ex vivo* ookinete development assay (Pb ODA) which simulates the first 22 h of parasite development in the mosquito (Delves M.J. et al., 2012), we report the screening, identification and profiling of new transmission-blocking molecules.

RESULTS

Screening of the TCAMS Library in the Pb ODA

The Pb ODA introduces gametocyte-infected mouse blood to compound-treated “ookinete medium” that simultaneously stimulates gametogenesis *ex vivo*. The readout of this assay is parasite expression of GFP under the control of an ookinete-specific promoter (CTRP) which is detected in a fluorescence plate reader. Therefore, this assay can measure the ability of a compound to inhibit parasite development from the onset of gametogenesis to ookinete formation – approximately the first 22 h of mosquito stage development.

The entire TCAMS library was screened in the Pb ODA at 1 μ M in duplicate independent experiments (Figure 1). A relatively lenient cut-off of >50% inhibition in one or both replicates was selected as the assay “primary-hit” criterion to permit even weakly active compounds to be investigated. Under these conditions, 550 compounds were identified (Supplementary Table S1). 513 of these compounds were available for resupply and were retested in dose response in



at least triplicate independent experiments which confirmed an $IC_{50} < 10 \mu M$ for 437 of them. Compounds with >70% inhibition in the primary screen exhibited a false positive discovery rate of 4.96% (Supplementary Tables S1, S2). Compounds with 50–69% inhibition in the primary screen, however, showed a false positive discovery rate of 31.66%, suggesting future Pb ODA screens should adopt a more stringent hit criteria of >70% inhibition. One compound with a pyridone scaffold (TCMDC-135461) exhibited a sub-nanomolar IC_{50} of < 0.2 nM (the lowest concentration tested in the dose response analysis). 21 additional compounds exhibited low-nanomolar IC_{50} s < 100 nM and a further 162 compounds possessed IC_{50} s < 1 μM (Supplementary Table S2).


Initial Profiling

The molecules active against *P. berghei* ookinete development were counter-screened for activity against *P. falciparum* asexual development in the growth inhibition assay (GIA), and additionally screened against HepG2 cells to determine

cytotoxicity (Supplementary Table S2). 92 compounds were more potent against HepG2 cells than against ookinete development and therefore were inferred to be cytotoxic (Figure 2A). 77 compounds were slightly parasite selective (1 to 10-fold more active against ookinete development), 190 showed good selectivity (>10 to 100-fold) and 83 were highly selective (>100-fold). After eliminating the cytotoxic compounds, the activity of those remaining were compared to activity in the Pf GIA (Figure 2B). Not a single compound had greater than 8-fold selectivity for *P. berghei* ookinetes over *P. falciparum* asexuals. Given that the TCAMS library is comprised entirely of compounds shown to have activity against *P. falciparum* asexuals, this is unsurprising; indeed 320 out of 441 compounds were more active against asexuals than ookinete development (Figure 2B).

Chemical Clustering Analysis

Molecular frameworks and fingerprint cluster analyses were used to structurally characterize the 437 confirmed hits, identifying 49 clusters and 128 singletons (Figure 3 and




Supplementary Table S2). In addition, many clusters contained compounds that shared a common functional scaffold and were grouped into seven different families comprising of pyridones, cyclic diaminopyrimidines, pyridyl derivatives, diaminopyrimidines, quinolones, tetrahydroisoquinolines, and benzodiazoles. The majority of compounds in the cyclic diaminopyrimidine group were found to be cytotoxic, however, most members of the other groups showed >10-fold parasite selectivity.

Profiling the Transmission-Blocking Properties of Selected Molecules

Exemplar molecules from the remaining six families showing high potency and parasite selectivity were selected for detailed parasitological profiling: TCMDC-135461 (pyridone); TCMDC-135907 (pyridyl derivative); TCMDC-134114 (diaminopyrimidine); TCMDC-137173 (quinolone); TCMDC-125849 (tetrahydroisoquinoline); TCMDC-124514 (benzodiazole) (Figure 4).

The selected molecules were evaluated for their ability to prevent mosquito transmission at 1 μM in *P. berghei* standard membrane feeding assays (Pb SMFA) (Figure 5A and Supplementary Table S3). Relative activity in the Pb SMFA broadly matched their activity in the Pb ODA, albeit with reduced potency. TCMDC-137173 and TCMDC-134114 both displayed low nanomolar activity in the Pb ODA (IC₅₀s < 60 nM). This translated into a 97–100% inhibition of oocyst intensity at 1 μM in the Pb SMFA. TCMDC-125849, TCMDC-135907 and TCMDC-124514 were less active in the Pb ODA (IC₅₀s > 250 nM) which translated into a 9–71% inhibition of oocyst intensity at 1 μM in the Pb SMFA. TCMDC-135461, the pyridone compound with the most potent activity in the Pb ODA was tested in the Pb SMFA in dose response at 1 μM , 100 nM, and 10 nM (Figure 5B and Supplementary Table S4). At 1 μM , no oocysts were observed in any mosquitoes. At 100 nM, oocyst intensity was reduced by 77.9% ($\pm 11.8\%$ standard error of the mean – SEM). At 10 nM, oocyst intensity was inhibited by 43% ($\pm 13.7\%$ SEM). Taken together, based upon the direct comparison of these six compounds in the Pb ODA and Pb SMFA, it would appear that a Pb ODA IC₅₀ of at least ~ 60 nM translates into a near-total transmission-blockade in mosquito feeds at 1 μM and should set the approximate threshold onward progression of molecules in future screens.


To ensure that data obtained using a rodent malaria parasite shows applicability to human malaria-infective species, the six molecules were tested in an established *P. falciparum* Dual Gamete Formation Assay (Pf DGFA). The Pf DGFA evaluates the ability of test molecules to prevent male and female gametocytes from differentiating into gametes *in vitro*, which is the first step of parasite development in the mosquito (Ruecker et al., 2014; Delves et al., 2018). Activity in the Pf DGFA has been shown to be highly predictive of activity in *P. falciparum* SMFAs which are technically difficult and expensive to perform (Ruecker et al., 2014; Baragaña et al., 2015). At 1 μM a diverse range of activities was observed against male and female *P. falciparum* gametocytes (Figure 5C and Supplementary Table S4). TCMDC-135461 and TCMDC-137173 – the two most potent compounds in the Pb ODA showed 75.4 and 76.7% inhibition of male gametocyte functional viability respectively, but low activity against female gametocytes (27.4 and 21.0% inhibition respectively). This indicates that these compounds are more active against male gametocytes than female gametocytes. TCMDC-134114 gave 97.0% inhibition of male gametocyte functional viability and was not active against female gametocytes – suggesting a male-specific mode of action. In contrast, TCMDC-125849 and TCMDC-124514 showed activity against both male (65.5 and 95.6% inhibition respectively) and female (99.3 and 90.7% inhibition respectively) gametocytes suggesting a mode of action targeting biochemical pathways fundamental to both gametocyte sexes. Finally, TCMDC-135907 showed little-to-no activity in the Pf DGFA, perhaps suggesting that this compound targets parasite development post-gamete formation (hence active in the Pb ODA and not Pf DGFA).



Comparison to Other Transmission-Blocking Assays

With regards to potential for transmission-blocking, the TCAMS library has also been previously screened against purified *P. falciparum* late stage (stages IV-V) gametocytes in an ATP depletion assay (Pf GC-ATP) (Almela et al., 2015), and purified *P. falciparum* female gametocytes in a female gametogenesis

assay (Pf FGAA) (Miguel-Blanco et al., 2017). In the Pf GC-ATP assay, the TCAMS were initially screened at 5 μ M and yielded 363 molecules with an IC₅₀ < 10 μ M, and in the Pf FGAA they were screened at 2 μ M, yielding 405 active compounds. In parallel, both studies also performed counterscreens against HepG2 cells for cytotoxicity. Combining these data with the Pb ODA screen results reported here and only considering molecules





with a >10-fold parasite specificity in their respective assay gives a collection of transmission-blocking molecules with a range of different phenotypes (Figure 6 and Supplementary Table S5). Nevertheless, molecules from all three assays have demonstrated transmission-blocking activity in mosquito feeds (Almela et al., 2015; Miguel-Blanco et al., 2017; Colmenarejo et al., 2018).

DISCUSSION

The TCAMS library is the largest collection of antimalarial molecules in the public domain and has sparked several major antimalarial drug discovery campaigns. Antimalarial molecules that have additional transmission-blocking activity have the potential to make a significant contribution to malaria elimination and eradication and are prioritized for development (Burrows et al., 2017). The Pb ODA is a simple and relatively inexpensive assay that can characterize the transmission-blocking activity of hundreds of molecules with the gametocyte infected blood of a single mouse (compared to Pb SMFAs which can evaluate ~2 molecules per mouse). It correlates well with SMFA data and the majority of identified molecules are also active against *P. falciparum* sexual stages.

TCMDC-135461, the representative pyridone molecule selected for profiling was the most potent molecule active in the Pb ODA but was less active against male and female gametocytes in the Pf DGFA. Other pyridones are known to act by targeting the parasite respiratory chain by inhibiting cytochrome *bc*₁ (Capper et al., 2015). Supporting this activity, mitochondrial respiration is essential for mosquito stage parasite development

(Goodman et al., 2016) and other cytochrome *bc*₁ inhibitors such as atovaquone are established transmission-blocking molecules (Fowler et al., 1995). However, phase-1 clinical trials of the pyridone antimalarial molecule GSK932121 were halted after it showed acute cardiotoxicity in rats, thought to be through inhibition of mammalian cytochrome *bc*₁ (Capper et al., 2015). This suggests higher selectivity is required for other pyridones to be used as orally administered antimalarials. Recently, contact exposure of mosquitoes to atovaquone has shown to inhibit parasite development in the mosquito (Paton et al., 2019). This reinforces the potential of parasite cytochrome *bc*₁ inhibitors as transmission blocking agents. Given the extreme potency of TCMDC-135461, indoor residual spraying and/or baited sugar traps may be a practical, efficacious and safer method of utilizing this class of molecules to elicit a transmission-blocking response. TCMDC-134114, the representative diaminopyrimidine molecule was also potent in the Pb ODA and Pb SMFA. Interestingly it had male gametocyte-specific activity in the Pf DGFA. The diaminopyrimidine scaffold is found in many molecules targeting dihydrofolate reductase (DHFR), such as the antimalarial pyrimethamine. DHFR is required for parasite folate biosynthesis which is essential for generating the nucleotides required for DNA replication (Heinberg and Kirkman, 2015). Male gametogenesis requires three rounds of endomitosis to generate eight male gametes. In addition, ookinete development requires one round of meiosis. Therefore, activity in the Pb ODA (which includes male gametogenesis and ookinete development) and male-specific activity against gametocytes in the Pf DGFA is consistent with this mode of action for TCMDC-134114. Datamining the chemical structure of TCMDC-137173 (the



representative quinolone compound) revealed that it is the established antimalarial quinolone endochin which was first reported in 1948 (Doggett et al., 2012). Since then, several endochin-like antimalarials have been developed, however, poor oral bioavailability has hampered their clinical progress (Nilsen et al., 2013; Miley et al., 2015). Like the pyridones, TCMDC-137173/endochin targets the parasite mitochondrial cytochrome *bc*₁ complex and therefore displays a transmission-blocking profile similar to TCMDC-135461. TCMDC-125849, the representative tetrahydroisoquinoline was moderately active in the Pb ODA with an IC₅₀ of 268 nM. Reflecting this, it gave only 71.4% inhibition of oocyst intensity in the Pb SMFA at 1 μ M. Supporting this level of transmission-blocking activity, 2 μ M TCMDC-125849 reportedly gives 100% inhibition of oocyst intensity and total inhibition of male gametogenesis in *P. falciparum* (Colmenarejo et al., 2018). The chemical structure of TCMDC-125849 closely resembles emetine – a known antiprotozoal compound which inhibits protein synthesis (Toyé et al., 1977; Wong et al., 2014). Supporting this hypothesis of targeting such a fundamental biological pathway, 1 μ M TCMDC-125849 inhibited both male and female gametogenesis (**Figure 5C**). In particular, female gametogenesis was inhibited by 99.3%. The female readout of the Pf DGFA relies on antibody detection of female gamete expression of Pfs25, which is held under translational repression in the female gametocyte. Therefore, inhibition of protein synthesis by TCMDC-125849 would be predicted to strongly reduce Pfs25 expression as observed. The representative benzodiazole TCMDC-124514 was also moderately active in the Pb ODA with an IC₅₀ of 397 nM which was reflected by low inhibition of oocyst intensity (9.1%

inhibition) in the Pb SMFA. Interestingly at 1 μM it potently inhibited both male and female gametogenesis suggesting it targets biology fundamental to both gametocyte sexes. In support of this, TCMDC-124514 has been hypothesized to be a Coenzyme A biosynthesis inhibitor (Weidner et al., 2017) which would both affect energy and lipid metabolism – both fundamental pathways within the parasite. The difference in species activity suggest that TCMDC-124514 is more active against *P. falciparum* than *P. berghei*. The representative pyridyl derivative, TCMDC-135907 showed moderate activity in the Pb ODA with an IC_{50} of 381 nM, which again was reflected incomplete inhibition at 1 μM in the Pb SMFA. There is no data in the literature to suggest a mode of action for this compound, however, data presented here suggests it targets the parasite after gamete formation.

When comparing the activities of several high throughput transmission assays against the TCAMS collection, it is clear to see that no single assay is sufficient to identify all transmission-blocking molecules. Likely this is due to the distinct (but overlapping) cell biology that they interrogate. To date, a high throughput assay that incorporates the entire cell biology of transmission does not exist. Therefore, to maximize the discovery of new transmission-blocking antimalarials, it would be prudent to use several assays and not rely on the data generated by a single assay alone.

MATERIALS AND METHODS

Compound Handling

The TCAMS library was provided in duplicate on assay-ready 384 well plates by GSK. 50 nl of each compound in 100% DMSO was stamped into each well with one column containing DMSO-only (negative control) and one column containing cycloheximide at a final assay concentration of 10 μM (positive control). Assay plates were stored at -20°C until used. Compounds selected for further investigation were supplied by GSK as 10 mM stock solutions in 100% DMSO.

P. berghei Ookinete Development Assay (Pb ODA)

All work involving laboratory animals was performed in accordance with the EU regulations EU Directive 86/609/EEC and within the regulations of the United Kingdom Animals (Scientific Procedures) Act 1986. The Pb ODA was performed exactly as described in Delves M.J. et al. (2012). Female T0 mice were treated with an intraperitoneal (ip) injection of 200 μl 6 mg/ml phenylhydrazine to induce hyperreticulocytosis. Three days later, the treated mice were infected with approximately 10^8 parasites by ip injection of blood from a donor mouse infected with *Plasmodium berghei* expressing GFP under the control of the ookinete-specific CTRP promoter (Vlachou et al., 2004). Three days afterward, the presence of high levels of gametocytes were confirmed by stimulating and observing male gametogenesis (exflagellation). A drop of blood was sampled from the tail of each mouse and mixed with ookinete medium (RPMI medium with 25 mM HEPES, 2 mM L-glutamine,

2 g/l sodium bicarbonate, 50 mg/l hypoxanthine and 100 μM anthurenic acid, adjusted to pH 7.4, plus 20% FBS) under a coverslip on a glass slide. Ten minutes later vigorously beating exflagellation centers were observed by phase contrast microscopy and invariably showed >10 centers per field at $\times 40$ objective. Infected mice were anesthetized in batches of five, rapidly exsanguinated, blood pooled and immediately transferred to ookinete medium at a 1:20 dilution. 50 μl of blood/medium was then rapidly dispensed into each well of the assay plates using a Multidrop Combi automated dispenser (Thermo Scientific) and the plates incubated in a humidified incubator at 19°C in the dark for 22 h. GFP fluorescence was then measured in a fluorescence plate reader (BMG Labtech FluoSTAR Omega) and inhibition of ookinete production calculated in relation to the positive and negative controls using the formula: % inhibition of ookinete production = $100 - [(well_fluorescence - positive_control)/(negative_control - positive_control) \times 100]$.

Compound Clustering and Computational Analysis

Clustering was performed following the computational methods described in Gamo et al. (2010). Briefly, molecular frameworks were calculated using an in-house implementation of the algorithm described previously (Bemis and Murcko, 1996). Compounds were also classified in chemical families using the Daylight fingerprint methods with a Tanimoto similarity index of 0.85, following the procedures in the Daylight Information Systems manual (Daylight Chemical Information Systems, 2019). The dendrogram in **Figure 3** was constructed using data obtained from the FragFP clustering algorithm performed within OSIRIS DataWarrior Version 04.07.03 and visualized using Cytoscape Version 3.7.1.

P. berghei Standard Membrane Feeding Assays (Pb SMFAs)

Membrane feeding assays were performed essentially as described in Ramakrishnan et al. (2013). Briefly, a phenylhydrazine-treated mouse (see above) was infected with blood from a donor mouse infected with *P. berghei* 507 parasites that constitutively express GFP throughout the parasite life cycle (Janse et al., 2006). Three days later the infected mouse was rapidly exsanguinated and the parasite-infected blood diluted at 1:10 dilution in naïve mouse blood pre-warmed to 37°C . Working as quickly as possible, the blood mix was divided into 500 μl aliquots and mixed with test compounds or DMSO alone at appropriate concentrations (final DMSO concentration of 0.2%) and immediately added to plastic water-jacketed membrane feeders and fed to *Anopheles stephensi* SDA 500 strain mosquitoes. After the feed, mosquitoes were maintained at $19^{\circ}\text{C}/80\%$ relative humidity overnight before unfed mosquitoes were removed. Fed mosquitoes continued to be maintained on 8% fructose (w/v)/0.05% (w/v) p-aminobenzoic acid for 7 days before their midguts were dissected out and oocyst burden quantified using fluorescence microscopy and semi-automated counting analysis (Delves and Sinden, 2010). Data presented is the mean of three independent experiments.

***P. falciparum* Dual Gamete Formation Assay (Pf DGFA)**

Compounds were tested exactly as described in Ruecker et al. (2014) in the carry-over assay format. Briefly, functionally mature stage V male and female gametocytes were generated by seeding *P. falciparum* NF54 strain asexual cultures at 1% parasitemia and 4% hematocrit and replacing culture medium (RPMI medium with 25 mM HEPES, 2 mM L-glutamine, 2 g/l sodium bicarbonate, 50 mg/l hypoxanthine plus 10% human serum) daily for 14 days whilst maintaining a constant temperature of 37°C and a gas mix of 3% CO₂, 5% O₂, 92% N₂. Gametocyte cultures were diluted to 25 million cells/ml (including erythrocytes) and 200 µl added to each well of a round-bottomed 96 well plate containing test compounds. Plates also contained DMSO negative and 20 µM methylene blue positive control wells. After a 24 h incubation at 37°C, gametogenesis was stimulated by transferring the gametocytes to a flat-bottomed 96 well plate containing 10 µl of ookinete medium at room temperature. Twenty minutes later, the emergence of male gametes was recorded microscopically using phase contrast and ×10 objective lens. The plate was then further incubated at 26°C for another 24 h to allow emerged female gametes to maximally express Pfs25 on their cell surface. An anti-Pfs25 antibody (Mab 4B7) conjugated to the Cy3 fluorophore was added to the plates and female gametes detected by live fluorescence microscopy at ×10 objective. Data was then processed using custom image analysis algorithms and percent inhibition in respect to positive (methylene blue) and negative (DMSO) controls was calculated. Data presented is the mean of four independent biological repeats.

***P. falciparum* Asexual Growth Inhibition Assay (Pf GIA)**

The asexual activity of active compounds was tested in dose response with parasite lactate dehydrogenase (LDH) activity used as a readout of parasite viability as described in Gamo et al. (2010). Briefly, 3D7-strain *P. falciparum* asexual parasites were diluted to 0.25% parasitemia, 2% hematocrit in culture medium composed of RPMI medium with 25 mM HEPES, 2% D-sucrose, 0.3% L-glutamine, 150 µM hypoxanthine plus 5% albumax. 25 µl of parasite inoculum was then dispensed into each well of a 384 well plate containing test compounds and positive (50 µM chloroquine) and negative (DMSO) controls. Plates were incubated for 72 h at 37°C in a 5% CO₂, 5% O₂, 90% N₂ environment before being frozen at -70°C. Plates were then thawed and 70 µl of reaction mix (143 mM sodium L-lactate, 143 mM 3-acetyl pyridine adenine dinucleotide, 178.75 mM Nitro Blue tetrazolium chloride, 286 mg/ml diaphorase (2.83 U/ml), 0.7% Tween 20, 100 mM Tris-HCl pH 8.0) was added to each well using a Multidrop Combi automated dispenser. Plates were shaken to mix and then absorbance at 650 nm was measured after 10 min incubation at room temperature. Percent inhibition of asexual growth was then calculated with respect to positive and negative controls. Data presented is the mean of three independent biological replicates.

HepG2 Cytotoxicity Assay

The activity of active compounds against HepG2 cells was performed as described in Delves et al. (2018). Briefly, HepG2 cells were seeded onto compound-treated 384 well plates at a density of 2,500 cells per well in Minimal Essential Medium (MEM) plus 10% fetal bovine serum and 1% non-essential amino acids solution (NEAA). Cells were incubated with test compounds or 50 µM doxorubicin (positive) and DMSO (negative) controls at 37°C for 48 h in a humidified 5% CO₂ atmosphere. Plates were then treated with Resazurin to a final concentration of 45 µM for 4 h. Cell viability was then measured in a fluorescent plate reader and percent inhibition calculated with respect to positive and negative controls.

DATA AVAILABILITY

All datasets generated for this study are included in the manuscript and/or **Supplementary Files**.

ETHICS STATEMENT

The animal study was reviewed and approved by Imperial College Animal Welfare Ethical Review Body.

AUTHOR CONTRIBUTIONS

MD, RS, F-JG, and DL designed the study. MD performed the Pb ookinete assay. ML-M performed the chemical clustering analysis. MD and LU performed the Pb SMFAs. AR performed the Pf DGFA.

FUNDING

This work was supported by a grant to RS from the Medicines for Malaria Venture (#MMV 08/2800/01). MD was funded by a Wellcome/LSHTM ISSF Fellowship.

ACKNOWLEDGMENTS

We would like to acknowledge Mark Tunnicliff for provision of mosquitoes and Dolores Jimenez-Alfaro for providing support in compound handling and platemap design.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmicb.2019.02134/full#supplementary-material>

REFERENCES

- Almela, M. J., Lozano, S., Lelièvre, J., Colmenarejo, G., Coterón, J. M., Rodrigues, J., et al. (2015). A new set of chemical starting points with *Plasmodium falciparum* transmission-blocking potential for antimalarial drug discovery. *PLoS One* 10:e0135139. doi: 10.1371/journal.pone.0135139
- Baragaña, B., Hallyburton, I., Lee, M. C. S., Norcross, N. R., Grimaldi, R., Otto, T. D., et al. (2015). A novel multiple-stage antimalarial agent that inhibits protein synthesis. *Nature* 522, 315–320. doi: 10.1038/nature14451
- Bemis, G. W., and Murcko, M. A. (1996). The properties of known drugs. 1. molecular frameworks. *J. Med. Chem.* 39, 2887–2893.
- Burrows, J. N., Duparc, S., Gutteridge, W. E., Hooft van Huijsdijnen, R., Kaszubka, W., Macintyre, F., et al. (2017). New developments in anti-malarial target candidate and product profiles. *Malar. J.* 16:26. doi: 10.1186/s12936-016-1675-x
- Calderón, F., Vidal-Mas, J., Burrows, J., de la Rosa, J. C., Jiménez-Díaz, M. B., Mulet, T., et al. (2012). A divergent sar study allows optimization of a potent 5-ht2c inhibitor to a promising antimalarial scaffold. *ACS Med. Chem. Lett.* 3, 373–377. doi: 10.1021/ml300008j
- Capper, M. J., O'Neill, P. M., Fisher, N., Strange, R. W., Moss, D., Ward, S. A., et al. (2015). Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1. *Proc. Natl. Acad. Sci. U.S.A.* 112, 755–760. doi: 10.1073/pnas.1416611112
- Colmenarejo, G., Lozano, S., González-Cortés, C., Calvo, D., Sanchez-Garcia, J., Matilla, J. P., et al. (2018). Predicting transmission blocking potential of anti-malarial compounds in the mosquito feeding assay using *Plasmodium falciparum* male gamete inhibition assay. *Sci. Rep.* 8, 7764–7764. doi: 10.1038/s41598-018-26125-w
- Daylight Chemical Information Systems, (2019). *Dlight Theory Manual*. Available at: <https://www.daylight.com/dayhtml/doc/theory/index.html> (Accessed May 20, 2019).
- Delves, M. J., Miguel-Blanco, C., Matthews, H., Molina, I., Ruecker, A., Yahiya, S., et al. (2018). A high throughput screen for next-generation leads targeting malaria parasite transmission. *Nat. Commun.* 9:3805. doi: 10.1038/s41467-018-05777-2
- Delves, M. J., Ramakrishnan, C., Blagborough, A. M., Leroy, D., Wells, T. N. C., and Sinden, R. E. (2012). A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines. *Int. J. Parasitol.* 42, 999–1006. doi: 10.1016/j.ijpara.2012.08.009
- Delves, M., Plouffe, D., Scheurer, C., Meister, S., Wittlin, S., Winzeler, E. A., et al. (2012). The activities of current antimalarial drugs on the life cycle stages of *Plasmodium*: a comparative study with human and rodent parasites. *PLoS Med.* 9:e1001169. doi: 10.1371/journal.pmed.1001169
- Delves, M. J., and Sinden, R. E. (2010). A semi-automated method for counting fluorescent malaria oocysts increases the throughput of transmission blocking studies. *Malar. J.* 9:35. doi: 10.1186/1475-2875-9-35
- Doggett, J. S., Nilsen, A., Forquer, I., Wegmann, K. W., Jones-Brando, L., Yolken, R. H., et al. (2012). Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. *PNAS* 109, 15936–15941.
- Eziefula, A. C., Bousema, T., Yeung, S., Kanya, M., Owaraganise, A., Gabagaya, G., et al. (2013). Single dose primaquine for clearance of *Plasmodium falciparum* gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. *Lancet Infect. Dis.* 14, 130–139. doi: 10.1016/S1473-3099(13)70268-8
- Fowler, R. E., Sinden, R. E., and Pudney, M. (1995). Inhibitory activity of the antimalarial atovaquone (566C80) against ookinetes, oocysts, and sporozoites of *Plasmodium berghei*. *J. Parasitol.* 81, 452–458.
- Gamo, F.-J., Sanz, L. M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J.-L., et al. (2010). Thousands of chemical starting points for antimalarial lead identification. *Nature* 465, 305–310. doi: 10.1038/nature09107
- Goodman, C. D., Siregar, J. E., Mollard, V., Vega-Rodríguez, J., Syafruddin, D., Matsuoka, H., et al. (2016). Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes. *Science* 352, 349–353. doi: 10.1126/science.aad9279
- Heinberg, A., and Kirkman, L. (2015). The molecular basis of antifolate resistance in *Plasmodium falciparum*: looking beyond point mutations. *Ann. N. Y. Acad. Sci. U.S.A.* 1342, 10–18. doi: 10.1111/nyas.12662
- Janse, C. J., Franke-Fayard, B., and Waters, A. P. (2006). Selection by flow-sorting of genetically transformed, GFP-expressing blood stages of the rodent malaria parasite, *Plasmodium berghei*. *Nat. Protoc.* 1, 614–623.
- Miguel-Blanco, C., Molina, I., Bardera, A. I., Díaz, B., de Las Heras, L., Lozano, S., et al. (2017). Hundreds of dual-stage antimalarial molecules discovered by a functional gametocyte screen. *Nat. Commun.* 8, 15160. doi: 10.1038/ncomms15160
- Miley, G. P., Pou, S., Winter, R., Nilsen, A., Li, Y., Kelly, J. X., et al. (2015). ELQ-300 prodrugs for enhanced delivery and single-dose cure of malaria. *Antimicrob. Agents Chemother.* 59, 5555–5560. doi: 10.1128/AAC.01183-15
- Nilsen, A., LaCrue, A. N., White, K. L., Forquer, I. P., Cross, R. M., Marfurt, J., et al. (2013). Quinolone-3-diarylethers: a new class of antimalarial drug. *Sci. Transl. Med.* 5:177ra37. doi: 10.1126/scitranslmed.3005029
- Paton, D. G., Childs, L. M., Itoe, M. A., Holmdahl, I. E., Buckee, C. O., and Catteruccia, F. (2019). Exposing *Anopheles* mosquitoes to antimalarials blocks *Plasmodium parasite* transmission. *Nature* 567, 239–243. doi: 10.1038/s41586-019-0973-1
- Plouffe, D. M., Wree, M., Du, A. Y., Meister, S., Li, F., Patra, K., et al. (2016). High-throughput assay and discovery of small molecules that interrupt malaria transmission. *Cell Host Microbe* 19, 114–126. doi: 10.1016/j.chom.2015.12.001
- Rabinovich, R. N., Drakeley, C., Djimde, A. A., Hall, B. F., Hay, S. I., Hemingway, J., et al. (2017). malERA: an updated research agenda for malaria elimination and eradication. *PLoS Med.* 14:e1002456. doi: 10.1371/journal.pmed.1002456
- Ramakrishnan, C., Delves, M. J., Lal, K., Blagborough, A. M., Butcher, G., Baker, K. W., et al. (2013). Laboratory maintenance of rodent malaria parasites. *Methods Mol. Biol.* 923, 51–72.
- Raphemot, R., Lafuente-Monasterio, M. J., Gamo-Benito, F. J., Clardy, J., and Derbyshire, E. R. (2015). Discovery of dual stage malaria inhibitors with new targets. *Antimicrob. Agents Chemother.* 60, 1430–1437. doi: 10.1128/AAC.02110-15
- Ruecker, A., Mathias, D. K., Straschil, U., Churcher, T. S., Dinglasan, R. R., Leroy, D., et al. (2014). A male and female gametocyte functional viability assay to identify biologically relevant malaria transmission-blocking drugs. *Antimicrob. Agents Chemother.* 58, 7292–7302. doi: 10.1128/AAC.03666-14
- Sanz, L. M., Jiménez-Díaz, M. B., Crespo, B., De-Cozar, C., Almela, M. J., Angulo-Barturen, I., et al. (2011). Cyclopropyl carboxamides a novel chemical class of antimalarial agents identified in a phenotypic screen. *Antimicrob. Agents Chemother.* 55, 5740–5745. doi: 10.1128/AAC.05188-11
- Toyé, P. J., Sinden, R. E., and Canning, E. U. (1977). The action of metabolic inhibitors on microgametogenesis in *Plasmodium yoelii nigeriensis*. *Z. Parasitenkd* 53, 133–141.
- Vlachou, D., Zimmermann, T., Cantera, R., Janse, C. J., Waters, A. P., and Kafatos, F. C. (2004). Real-time, in vivo analysis of malaria ookinete locomotion and mosquito midgut invasion. *Cell. Microbiol.* 6, 671–685.
- Weidner, T., Lucantoni, L., Nasereddin, A., Preu, L., Jones, P. G., Dzikowski, R., et al. (2017). Antiplasmodial dihetarylthioethers target the coenzyme A synthesis pathway in *Plasmodium falciparum* erythrocytic stages. *Malar. J.* 16:192. doi: 10.1186/s12936-017-1839-3
- Williamson, A. E., Ylloja, P. M., Robertson, M. N., Antonova-Koch, Y., Avery, V., Baell, J. B., et al. (2016). Open source drug discovery: highly potent antimalarial compounds derived from the tres cantos arylpyrroles. *ACS Cent. Sci.* 2, 687–701.
- Wong, W., Bai, X., Brown, A., Fernandez, I. S., Hanssen, E., Condrón, M., et al. (2014). Cryo-EM structure of the *Plasmodium falciparum* 80S ribosome bound to the anti-protozoan drug emetine. *eLife* 3:e03080. doi: 10.7554/eLife.03080

Conflict of Interest Statement: F-JG and ML-M are employed by GlaxoSmithKline.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Delves, Lafuente-Monasterio, Upton, Ruecker, Leroy, Gamo and Sinden. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.